IL-18 is involved in vascular injury in end-stage renal disease patients

Nephrology Dialysis Transplantation

Volumn 24, Issue 2, 2009, Pages 589-596

  Porazko, Tomasz ^a   Kuźniar, Jakub ^a   Kusztal, Mariusz ^a   Kuźniar, Tomasz J ^b   Weyde, Wacław ^a   Kuriata Kordek, Magdalena ^a   Klinger, Marian ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b MAYO CLINIC   (United States)

Author keywords

Chronic kidney disease; ESRD; IL 18; Pulse wave velocity; Vascular injury

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CALCIUM; CALCIUM PHOSPHATE; CHOLESTEROL; FETUIN A; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 6; PARATHYROID HORMONE; PHOSPHATE; TRIACYLGLYCEROL;

ADULT; ARTERIAL STIFFNESS; ARTERIOSCLEROSIS; ARTERY COMPLIANCE; ARTICLE; BLOOD VESSEL INJURY; CALCIUM BLOOD LEVEL; CAROTID ARTERY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; FEMORAL ARTERY; FIBRINOGEN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY FAILURE; LEUKOCYTE COUNT; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NEPHRITIS; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE WAVE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; ARTERIOSCLEROSIS; BLOOD PROTEINS; BLOOD VESSELS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; ELASTICITY; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-18; INTERLEUKIN-6; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; RENAL DIALYSIS;

EID: 58449121399     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn486     Document Type: Article

References (48)

1. Blacher J, Safar ME, Guerin AP et al. Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney Int 2003; 63: 1852-1860.
2. Mourad JJ, Pannier B, Blacher J et al. Creatinine clearance, pulse wave velocity, carotid compliance and essential hypertension. Kidney Int 2001; 59: 1834-1841
3. London GM, Marchais SJ, Guerin AP et al. Arterial structure and function in end-stage renal disease. Nephrol Dial Transplant 2002; 17: 1713-1724
4. Schwarz U, Buzello M, Ritz E et al. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 2000; 15: 218-223
5. Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial 2002; 15: 329-337
6. Noh H, Lee SW, Kang SW et al. Serum C-reactive protein: a predictor of mortality in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1998; 18: 387-394
7. Owen WF, Lowrie EG. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 1998; 54: 627-636
8. Zimmermann J, Herrlinger S, Pruy A et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648-658
9. Blankenberg S, Tiret L, Bickel C et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002; 106: 24-30
10. Yamagami H, Kitagawa K, Hoshi T et al. Associations of serum IL-18 levels with carotid intima-media thickness. Arterioscler Thromb Vasc Biol 2005; 25: 1458-1462
11. Gangemi S, Mallamace A, Minciullo PL et al. Involvement of interleukin-18 in patients on maintenance haemodialysis. Am J Nephrol 2002; 22: 417-421
12. Descamps-Latscha B. The immune system in end-stage renal disease. Curr Opin Nephrol Hypertens 1993; 2: 883-891
13. Dinarello CA. IL-18: a TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol 1999; 103(Pt 1): 11-24
14. Girndt M, Sester U, Kaul H et al. Production of proinflammatory and regulatory monokines in hemodialysis patients shown at a single-cell level. J Am Soc Nephrol 1998; 9: 1689-1696
15. Ranjbaran H, Sokol SI, Gallo A et al. An inflammatory pathway of IFN-gamma production in coronary atherosclerosis. J Immunol 2007; 178: 592-604
16. Whitman SC, Ravisankar P, Daugherty A. Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-gamma. Circ Res 2002; 90: E34-8
17. Mallat Z, Corbaz A, Scoazec A et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001; 104: 1598-1603
18. Blankenberg S, Luc G, Ducimetiere P et al. Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 2003; 108: 2453-2459
19. Chiang CK, Hsu SP, Pai MF et al. Interleukin-18 is a strong predictor of hospitalization in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 2810-2815
20. Yano A, Nakao K, Sarai A et al. Elevated serum interleukin-18 levels might reflect the high risk of hospitalization in patients on peritoneal dialysis. Nephrology (Carlton) 2005; 10: 576-582
21. Mallat Z, Besnard S, Duriez M et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999; 85: e17-e24
22. Turner DM, Williams DM, Sankaran D et al. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 1997; 24: 1-8
23. Morita Y, Yamamura M, Kashihara N et al. Increased production of interleukin-10 and inflammatory cytokines in blood monocytes of hemodialysis patients. Res Commun Mol Pathol Pharmacol 1997; 98: 19-33
24. Seyrek N, Karayaylali I, Balal M et al. Is there any relationship between serum levels of interleukin-10 and atherosclerosis in hemodialysis patients? Scand J Urol Nephrol 2005; 39: 405-409
25. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483
26. Ketteler M, Bongartz P, 3Westenfeld R et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361: 827-833
27. Moe SM, Reslerova M, Ketteler M et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 2005; 67: 2295-2304
28. Lebreton JP, Joisel F, Raoult JP et al. Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest 1979; 64: 1118-1129
29. Chiang CK, Hsu SP, Pai MF et al. Plasma interleukin-18 levels in chronic renal failure and continuous ambulatory peritoneal dialysis. Blood Purif 2005; 23: 144-148
30. Cornish J, Gillespie MT, Callon KE et al. Interleukin-18 is a novel mitogen of osteogenic and chondrogenic cells. Endocrinology 2003; 144: 1194-1201
31. Covic A, Goldsmith DJ, Gusbeth-Tatomir P et al. Successful renal transplantation decreases aortic stiffness and increases vascular reactivity in dialysis patients. Transplantation 2003; 76: 1573-1577
32. Quan H, Shih WJ. Assessing reproducibility by the within-subject coefficient of variation with random effects models. Biometrics 1996; 52: 1195-1203
33. Sahar S, Dwarakanath RS, Reddy MA et al. Angiotensin II enhances interleukin-18 mediated inflammatory gene expression in vascular smooth muscle cells: a novel cross-talk in the pathogenesis of atherosclerosis. Circ Res 2005; 96: 1064-1071
34. Gupta S, Pablo AM, Jiang X et al. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest 1997; 99: 2752-2761
35. Lonnemann G, Novick D, Rubinstein M et al. Interleukin-18, interleukin-18 binding protein and impaired production of interferon-gamma in chronic renal failure. Clin Nephrol 2003; 60: 327-334
36. Descamps-Latscha B, Jungers P. New molecular aspects of chronic uraemia and dialysis-related immunocompetent cell activation. Nephrol Dial Transplant 1996; 2(Suppl 11): 121-124
37. Sester U, Sester M, Hauk M et al. T-cell activation follows Th1 rather than Th2 pattern in haemodialysis patients. Nephrol Dial Transplant 2000; 15: 1217-1223
38. Xu D, Chan WL, Leung BP et al. Selective expression and functions of interleukin 18 receptor on T helper (Th) type 1 but not Th2 cells. J Exp Med 1998; 188: 1485-1492
39. Gerdes N, Sukhova GK, Libby P et al. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med 2002; 195: 245-257
40. Nakamura A, Shikata K, Hiramatsu M et al. Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes Care 2005; 28: 2890-2895
41. Tso TK, Huang WN, Huang HY et al. Relationship of plasma interleukin-18 concentrations to traditional and non-traditional cardiovascular risk factors in patients with systemic lupus erythematosus. Rheumatology 2006; 45: 1148-1153
42. Girndt M, Kohler H, Schiedhelm-Weick E et al. Production of interleukin-6, tumor necrosis factor alpha and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. Kidney Int 1995; 47: 559-565
43. Girndt M, Ulrich C, Kaul H et al. Uremia-associated immune defect: the IL-10-CRP axis. Kidney Int Suppl 2003: S76-S79
44. Guerin AP, London GM, Marchais SJ et al. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15: 1014-1021
45. Savage T, Clarke AL, Giles M et al. Calcified plaque is common in the carotid and femoral arteries of dialysis patients without clinical vascular disease. Nephrol Dial Transplant 1998; 13: 2004-2012
46. Wang AY, Woo J, Wang M et al. Association of inflammation and malnutritionwith cardiac valve calcification in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol 2001; 12: 1927-1936
47. Stenvinkel P, Wang K, Qureshi AR et al. Low fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin. Kidney Int 2005; 67: 2383-2392
48. Hermans MM, Brandenburg V, Ketteler M et al. Study on the relationship of serum fetuin-A concentration with aortic stiffness in patients on dialysis. Nephrol Dial Transplant 2006; 21: 1293-1299